Human Endogenous Retroviruses in Neurodegenerative Diseases.

Alzheimer’s disease Parkinson’s disease amyotrophic lateral sclerosis biomarkers clinical trials frontotemporal dementia human endogenous retrovirus motor neuron disease multiple sclerosis neurodegenerative diseases retrotransposon

Journal

Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097

Informations de publication

Date de publication:
05 Jun 2024
Historique:
received: 10 05 2024
revised: 25 05 2024
accepted: 04 06 2024
medline: 27 6 2024
pubmed: 27 6 2024
entrez: 27 6 2024
Statut: epublish

Résumé

Human endogenous retroviruses (HERVs) are DNA transposable elements that have integrated into the human genome via an ancestral germline infection. The potential importance of HERVs is underscored by the fact that they comprise approximately 8% of the human genome. HERVs have been implicated in the pathogenesis of neurodegenerative diseases, a group of CNS diseases characterized by a progressive loss of structure and function of neurons, resulting in cell death and multiple physiological dysfunctions. Much evidence indicates that HERVs are initiators or drivers of neurodegenerative processes in multiple sclerosis and amyotrophic lateral sclerosis, and clinical trials have been designed to target HERVs. In recent years, the role of HERVs has been explored in other major neurodegenerative diseases, including frontotemporal dementia, Alzheimer's disease and Parkinson's disease, with some interesting discoveries. This review summarizes and evaluates the past and current research on HERVs in neurodegenerative diseases. It discusses the potential role of HERVs in disease manifestation and neurodegeneration. It critically reviews antiretroviral strategies used in the therapeutic intervention of neurodegenerative diseases.

Identifiants

pubmed: 38927681
pii: genes15060745
doi: 10.3390/genes15060745
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Gabrielle L Adler (GL)

Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
School of Medical Sciences, The University of Sydney, Sydney, NSW 2050, Australia.

Kelvin Le (K)

Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
School of Medical Sciences, The University of Sydney, Sydney, NSW 2050, Australia.

YuHong Fu (Y)

Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
School of Medical Sciences, The University of Sydney, Sydney, NSW 2050, Australia.

Woojin Scott Kim (WS)

Brain and Mind Centre, The University of Sydney, Sydney, NSW 2050, Australia.
School of Medical Sciences, The University of Sydney, Sydney, NSW 2050, Australia.
School of Biomedical Sciences, University of New South Wales, Sydney, NSW 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH